Although some studies suggested that GPR30 might promote the development of some reproductive system malignancies [19–21], combination therapy that contains low-dose E2 and the specific antagonist G15 of GPR30 for patients with postmenopausal osteoporosis may be a good choice for clinicians. The gene discussed is GPER1; the disease is postmenopausal osteoporosis.